Front Row Advisors’s Bio-Techne TECH Stock Holding History

Front Row Advisors’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-996	Closed	-$50K	–	1078
2019 Q1	$50K	Hold	996	–	–	0.04%	206
2018 Q4	$36K	Hold	996	–	–	0.03%	227
2018 Q3	$43K	Hold	996	–	–	0.03%	221
2018 Q2	$41K	Hold	996	–	–	0.03%	238
2018 Q1	$38K	Hold	996	–	–	0.03%	248
2017 Q4	$32K	Buy	+996	New	+$31.6K	0.03%	278

Other funds holding TECH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

MPI

Mairs & Power Inc St Paul, Minnesota $10.9B AUM 27.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Front Row Advisors's TECH Position: Q2 2019 in Review

Front Row Advisors sold out of Bio-Techne (TECH) in Q2 2019, closing a stake of 996 shares — an estimated $50K sold.

Front Row Advisors first reported a position in TECH in Q4 2017 and held it in 6 quarters. The position peaked at $50K in Q1 2019. 369 funds tracked by Wall St. Rank hold TECH as of Q2 2019.

Front Row Advisors reported no remaining Bio-Techne position as of Q2 2019 after selling out during the quarter.
Front Row Advisors sold 996 Bio-Techne shares in Q2 2019, an estimated $50K.
Front Row Advisors first reported a position in Bio-Techne in Q4 2017 and held it in 6 quarters.
Front Row Advisors's Bio-Techne position peaked at $50K in Q1 2019.
369 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2019.

Based on Front Row Advisors's 13F filing for Q2 2019, filed 27 Aug 2019.